These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28454427)

  • 1. Chemoresistance in pancreatic cancer: Emerging concepts.
    Gnanamony M; Gondi CS
    Oncol Lett; 2017 Apr; 13(4):2507-2513. PubMed ID: 28454427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy for pancreatic cancer.
    Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
    Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
    Kieler M; Unseld M; Bianconi D; Schindl M; Kornek GV; Scheithauer W; Prager GW
    J Clin Med; 2020 Feb; 9(3):. PubMed ID: 32121198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
    Liu GF; Li GJ; Zhao H
    J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adjuvant Chemotherapy after Surgery for Pancreatic Cancer].
    Furuse J
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):160-4. PubMed ID: 27067680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
    Woo W; Carey ET; Choi M
    Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of pancreatic cancer. Actuality and perspective].
    Bittoni A; Andrikou K; Lanese A; Santoni M; Pellei C; Faloppi L; Del Prete M; Giampieri R; Cascinu S
    Recenti Prog Med; 2015 May; 106(5):208-16. PubMed ID: 25994537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
    J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer: systemic combination therapies for a heterogeneous disease.
    Melisi D; Calvetti L; Frizziero M; Tortora G
    Curr Pharm Des; 2014; 20(42):6660-9. PubMed ID: 25341938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving treatment landscape for early and advanced pancreatic cancer.
    Lau SC; Cheung WY
    World J Gastrointest Oncol; 2017 Jul; 9(7):281-292. PubMed ID: 28808501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).
    Uccello M; Moschetta M; Mak G; Alam T; Henriquez CM; Arkenau HT
    Curr Oncol; 2018 Feb; 25(1):e90-e94. PubMed ID: 29507500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized Pancreatic Cancer: Multidisciplinary Management.
    Coveler AL; Herman JM; Simeone DM; Chiorean EG
    Am Soc Clin Oncol Educ Book; 2016; 35():e217-26. PubMed ID: 27249726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer.
    Kurimoto M; Kimura M; Usami E; Iwai M; Hirose T; Kawachi S; Yoshimura T
    Mol Clin Oncol; 2017 Jul; 7(1):125-130. PubMed ID: 28685089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in pancreatic cancer: Promises and failures.
    Barati Bagherabad M; Afzaljavan F; ShahidSales S; Hassanian SM; Avan A
    J Cell Biochem; 2019 Mar; 120(3):2726-2741. PubMed ID: 28703890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.